Latest Sales Growth News

Baby Bunting delivered a standout FY25 with pro forma NPAT soaring 228% to $12.1 million, driven by record sales and a successful store refurbishment program. The retailer’s growth strategy is gaining momentum as it plans an aggressive rollout of its ‘Store of the Future’ concept.

Baby Bunting Group Limited reported a remarkable 462% increase in statutory net profit after tax for FY2025, driven by strong sales growth and strategic store refurbishments. The company also advanced its sustainability initiatives and expanded its digital and retail media businesses.

Meridian Energy's July report reveals a notable decline in hydro storage levels alongside a surge in retail electricity sales, highlighting a complex energy landscape in New Zealand.

OMG Group has secured placement of its Blue Dinosaur products in 750 7-Eleven stores nationwide, marking a pivotal step in its multi-channel expansion strategy and following record quarterly cash receipts.

Euro Manganese Inc. has bolstered its development of the Chvaletice Manganese Project with new financing and critical regulatory approvals, while progressing offtake discussions amid ongoing market uncertainties.

RooLife Group Ltd has successfully raised $2 million through an oversubscribed strategic placement, positioning the company to expand its e-commerce footprint across key international markets.

JB Hi-Fi Limited reported a robust 10% increase in FY25 sales to AUD 10.55 billion, alongside a strategic dividend hike and a planned CEO transition, signaling confidence in future growth.

DroneShield launches SentryCiv, a subscription-based AI-powered counter-drone solution designed to protect civilian critical infrastructure from emerging aerial threats.

JB Hi-Fi reported a robust FY25 with 10% sales growth and increased dividends, while preparing for a leadership change.

Nick Scali Limited reported a resilient FY25 with solid sales growth in Australia and New Zealand, while UK operations continue to improve margins despite ongoing losses. The company declared a fully franked dividend and outlined plans for further expansion.

Nick Scali Limited reported a solid FY25 underlying profit of $62 million, driven by strong ANZ sales and online growth, while UK operations continue to struggle amid store refurbishments and brand repositioning.

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.